Early interim 2-(1)fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to peripheral blood lymphocyte/monocyte ratio at diagnosis in classical Hodgkin's lymphoma

Haematologica

Volumn 97, Issue 6, 2012, Pages

  Romano, Alessandra ^a   Vetro, Calogero ^a   Donnarumma, Daniela ^a   Forte, Stefano ^b   Ippolito, Massimo ^c   di Raimondo, Francesco ^a  

^a UNIVERSITY OF CATANIA   (Italy)

^b IOM Ricerca srl   (Italy)

^c CANNIZZARO HOSPITAL   (Italy)

Author keywords

Absolute; Count; Diagnosis; Hodgkin's lymphoma; Lymphocyte; Monocyte; PET 2

Indexed keywords

BLEOMYCIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; FLUORODEOXYGLUCOSE; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE;

ADULT; AGED; AUTOTRANSPLANTATION; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DISEASE COURSE; DISEASE FREE SURVIVAL; FEMALE; HODGKIN DISEASE; HUMAN; LETTER; LYMPHOCYTE COUNT; LYMPHOCYTE MONOCYTE RATIO; MAJOR CLINICAL STUDY; MALE; MONOCYTE; MULTIPLE CYCLE TREATMENT; PREDICTIVE VALUE; PROGRESSION FREE SURVIVAL; SENSITIVITY AND SPECIFICITY; TREATMENT FAILURE;

FEMALE; HODGKIN DISEASE; HUMANS; LYMPHOCYTES; MALE; MONOCYTES;

EID: 84862123291     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2012.064576     Document Type: Letter

References (10)

1. Santoro A, Bonadonna G. Prolonged disease-free survival in MOPPresistant Hodgkin's disease after treatment with adriamycin, bleomycin, vinblastine and dacarbazine (ABVD). Cancer Chemother Pharmacol. 1979;2(2):101-5.
2. Engert A, Diehl V, Franklin J, Lohri A, Dörken B, Ludwig WD, et al. Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study. J Clin Oncol. 2009;27(27):4548-54.
3. Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med. 1998;339(21):1506-14.
4. Hasenclever D. The disappearance of prognostic factors in Hodgkin's disease. Ann Oncol. 2002;13(Suppl 1):75-8.
5. Gallamini A, Hutchings M, Rigacci L, Specht L, Merli F, Hansen M, et al. Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study. J Clin Oncol. 2007;25(24):3746-52.
6. Steidl C, Lee T, Shah SP, Farinha P, Han G, Nayar T, et al. Tumorassociated macrophages and survival in classic Hodgkin's lymphoma. N Engl J Med. 2010;362(10):875-85.
7. Harris JA, Jain S, Ren Q, Zarineh A, Liu C, Ibrahim S. CD163 Versus CD68 in Tumor Associated Macrophages of Classical Hodgkin Lymphoma. Diagn Pathol. 2012;7(1):12.
8. Azambuja D, Natkunam Y, Biasoli I, Lossos IS, Anderson MW, Morais JC, et al. Lack of association of tumor-associated macrophages with clinical outcome in patients with classical Hodgkin's lymphoma. Ann Oncol. 2012;23(3):736-42.
9. Porrata LF, Ristow K, Colgan JP, Habermann TM, Witzig TE, Inwards DJ, et al. Peripheral blood lymphocyte/monocyte ratio at diagnosis and survival in classical Hodgkin's lymphoma. Haematologica. 2012;97(2):262-9.
10. Cheson BD. The International Harmonization Project for response criteria in lymphoma clinical trials. Hematol Oncol Clin North Am. 2007;21(5):841-54.